Skip to main
leh kem' bee LEQEMBI Your browser does not support the audio element. speaker speaker speaker active
leh kan' uh mab lecanemab Your browser does not support the audio element. speaker speaker speaker active
Medication Guide
Prescribing Information
  • For US residents only

  • Important Safety
    Information
  • Prescribing
    Information
  • Medication
    Guide
  • Healthcare
    Provider Site
Leqembi

For US residents only

Visita el sitio en español
  • Early
    Alzheimer’s
    • What is mild cognitive impairment?
    • What is early Alzheimer's disease?
    • Stages of Alzheimer's disease
    • Tests you should know about
  • About
    LEQEMBI
    • How does LEQEMBI work?
    • LEQEMBI study results
    • Potential side effects
    • Starting your LEQEMBI conversation
  • Getting
    started
    • What to expect
    • Preparing for infusions
  • Support
    & resources
    • Insurance & financial support
    • LEQEMBI Companion™
    • Downloadable resources
    • Hear patient stories
    • Advocacy organizations
    • Sign up for more information
    • Frequently Asked Questions
  • For care
    partners
    • Supporting your loved one
    • Taking care of yourself
  • Eisai Patient Support
    1-833-453-7362
  • Important Safety
    Information
  • Healthcare Provider Site
  • LEQEMBI Your browser does not support the audio element. speaker speaker active
    lecanemab Your browser does not support the audio element. speaker speaker active
Visita el sitio en español >

NOW FDA APPROVED

Once-monthly (once every 4 weeks) maintenance infusions are available after 18 months. Learn more.

Audrey and her son, Denver, on a walk
Audrey and her son, Denver, on a walk

AUDREY

living with mild Alzheimer's
dementia,* and her son, Denver

*Patient shown is not taking LEQEMBI.

Patient information is accurate as of November 2024.

SITE MAP

  • Early Alzheimer’s
  • What is mild cognitive impairment?
  • What is early Alzheimer's disease?
  • Stages of Alzheimer’s disease
  • Tests you should know about
  • About LEQEMBI
  • How does LEQEMBI work?
  • LEQEMBI study results
  • Potential side effects
  • Starting your LEQEMBI conversation
  • Getting started
  • What to expect
  • Preparing for infusions
  • Support & resources
  • Insurance & financial support
  • LEQEMBI Companion™
  • Downloadable resources
  • Hear patient stories
  • Advocacy organizations
  • Sign up for more information
  • Frequently Asked Questions
  • For care partners
  • Supporting your loved one
  • Taking care of yourself

IMPORTANT SAFETY INFORMATION

WHAT IS LEQEMBI?

LEQEMBI is a prescription medicine used to treat people with early Alzheimer’s disease,
which includes mild cognitive impairment (MCI) or mild dementia stage of disease.

EXPAND COLLAPSE

WHAT IS LEQEMBI?

LEQEMBI is a prescription medicine used to treat people with early Alzheimer’s disease,
which includes mild cognitive impairment (MCI) or mild dementia stage of disease.

WHAT IS LEQEMBI?

LEQEMBI is a prescription medicine used to treat people with early Alzheimer’s disease,
which includes mild cognitive impairment (MCI) or mild dementia stage of disease.

IMPORTANT SAFETY
INFORMATION

Information icon

What is the most important information I should know about LEQEMBI?

LEQEMBI can cause serious side effects, including:

ARIA (Amyloid-Related Imaging Abnormalities). ARIA is a side effect that does not usually cause any symptoms, but serious symptoms can occur. ARIA can be fatal.

  • ARIA commonly shows up as temporary swelling in areas of the brain that usually goes away over time

  • Small spots of bleeding in or on the
    surface of the brain can occur

  • Less often, larger areas of bleeding in the brain can
    occur

  • Most people with ARIA don’t have any
    symptoms. However, some people may notice:

    – headache

    – confusion that gets worse

    – dizziness

    – vision changes

    – nausea

    – difficulty walking

    – seizures

  • Some people have a gene called ApoE4 that may increase the risk of ARIA. Talk to your healthcare provider about testing to see if you have this gene

  • You may be at a higher risk of developing bleeding in the brain if you take medicines to reduce blood clots from forming (antithrombotic medicines) while receiving LEQEMBI. Talk to your healthcare provider to see if any of the medicines you’re taking increase this risk

  • Your healthcare provider will check for ARIA with MRI (magnetic resonance imaging) scans before you start LEQEMBI and
    during treatment

  • You should carry information that says you are receiving LEQEMBI, which can cause ARIA, and that ARIA symptoms can look like stroke symptoms

Phone with text bubble icon

Call your healthcare provider or go to the nearest hospital emergency room right away if you have any of the symptoms listed above.

Most common side effects icon

Serious allergic reactions:

Do not receive LEQEMBI if you have serious allergic reactions to LEQEMBI or any of the ingredients in LEQEMBI.

  • Tell your healthcare provider if you notice any symptoms during or after a LEQEMBI infusion, including:

    – swelling of the face, lips, mouth, or tongue

    – itchy bumps on the skin,
    also known as hives

    – difficulty breathing

Infusion-related reactions:

  • Tell your healthcare provider right away if you notice any of these symptoms during
    a LEQEMBI infusion:

    – fever

    – flu-like symptoms (chills, body aches, feeling shaky, joint pain)

    – nausea and/or vomiting

    – dizziness or lightheadedness

    – fast or slow heart rate, or feeling like your chest is pounding

    – difficulty breathing or shortness of breath

  • If you have an infusion-related reaction, your healthcare provider may give you medicines before your next infusion to lower the chance of having a reaction

Most common side effects icon
The most common side effects of LEQEMBI include infusion-related reactions, ARIA, and headaches.

These are not all the possible side effects of LEQEMBI. Call your doctor for more information
and medical advice about side effects. You may report side effects to the FDA at
www.fda.gov/medwatch or call 1-800-FDA-1088.

Conversation bubble icon

Before receiving LEQEMBI, tell your healthcare provider about:

  • All your medical conditions, including if you are pregnant, breastfeeding, or plan to become pregnant or breastfeed. It is not known if LEQEMBI could harm your unborn or breastfeeding baby

  • All the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take medicines to reduce blood clots from forming (antithrombotic medicines, including aspirin)

Please read the full Prescribing Information including Boxed WARNING, and Medication Guide for LEQEMBI.

 

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.

This site is intended for residents of the United States only. The products discussed herein may have different product labeling in different countries. This Website contains information relating to various medical conditions and treatment. Such information is provided for educational purposes only and is not meant to be a substitute for the advice of a physician or other healthcare professionals. You should not use this information for diagnosing a health problem or disease. In order for you to make intelligent healthcare decisions, you should always consult with a physician or other healthcare provider for your, or your loved ones’, personal medical needs. Individual responses to treatment may vary.

  • About Eisai
  • Privacy Statement
  • Site Map
  • Cookie Preferences
  • Legal Notices
  • Facebook
Eisai logo
Biogen logo

© 2025 Eisai Inc. and Biogen.
LEQE-US4128 March 2025
All trademarks are the property of their respective owners.
LEQEMBI® is a registered trademark of Eisai R&D Management Co., Ltd.
LEQEMBI Companion™ is a trademark of Eisai R&D Management Co., Ltd.

You are now leaving LEQEMBI.com.

Eisai Inc. does not endorse the following website, nor does Eisai Inc. review the information contained on the following website for content, accuracy, or completeness.

CONTINUE

This site is for US healthcare providers only.

Select “Continue” to verify that you are a US healthcare professional or “Cancel” to return to the previous page.

CONTINUE

You are now leaving LEQEMBI.com.

This tool is developed, hosted, and maintained by NICA, an organization independent from Eisai. Eisai does not control or validate the content on the NICA Infusion Center* Locator website. Eisai is not endorsing or recommending any particular infusion provider by making this link available. The Locator does not provide a comprehensive list of infusion providers, and other infusion providers may be available to patients.

*The NICA Infusion Center serves as a tool to connect patients with the most accessible infusion center in their area, and for providers to find referral sites. Patients should contact the center directly with medication offerings, referral, insurance, scheduling availability, and other site-specific questions.

CONTINUE